Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Frequently asked questions
What sector does TREVENA INC. DL-001 (6T40) operate in?
TREVENA INC. DL-001 belongs to the Healthcare sector and operates in the Biotechnology industry.
What is TREVENA INC. DL-001 (6T40) current stock price?
As of the latest data, TREVENA INC. DL-001 stock price is €0.20, with a previous close of €0.21. TREVENA INC. DL-001 lost -€0.01 in the last trading session, representing a -2.91% loss.
What is TREVENA INC. DL-001 (6T40) current market capitalization?
TREVENA INC. DL-001 market cap is approximately 146.73 thousand.
What is TREVENA INC. DL-001 (6T40) Earnings Per Share (EPS)?
The trailing EPS is -€51.67.
Does TREVENA INC. DL-001 (6T40) pay dividends?
No. TREVENA INC. DL-001 does not pay a dividend.
What is TREVENA INC. DL-001 (6T40) beta (volatility) score?
TREVENA INC. DL-001 has a beta of 1.051, meaning its volatility is roughly in line with the market.
